Skip to main content

Closed

ICCC: ImmuCell Corporation Stock Analysis | finqOS

Healthcare · Biotechnology

Loading chart data...

Current StateBalance holding

The verdict

Good business

Strong

Revenue growth+51.6% / yr

Operating margin8.4%

ROIC6.0%

Financially safe

Strong

Debt / equity0.44×

Interest coverage5.4×

Current ratio4.82×

ImmuCell Corporation

ICCCNASDAQ Capital Market·USD·Closed

ImmuCell Corporation

ICCCNASDAQ·USD·Closed

$11.21

+1.36%

$11.21

+$0.15 (1.36%)

52W Range

88thpctl

Volume

0.33×avg

Mkt Cap

101.41MUSD

P/E

-187.5TTM

Div Yield

–ann

52W Range

88thpctl

Volume

0.33×avg

Market Cap

101.41MUSD

P/E Ratio

-187.5TTM

Div Yield

-ann

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings